The results of this study support the evidence from molecular studies pointing to the interaction between tau and amyloid in AD pathogenesis, showing that the combination of amyloid and tau is a better predictor IADL impairment than either biomarker alone. The gene discussed is MAPT; the disease is Alzheimer disease.